MedTrace Logo

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

NCT00956787 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-06-24

No results posted yet for this study

Summary

The purpose of this study is to determine if AR-67 is effective in the treatment for patients with MDS.

Conditions

Interventions

DRUG

AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)

Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.

Sponsors & Collaborators

  • Arno Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jorge Cortes, MD · The University of Texas MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2014-07-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00956787 on ClinicalTrials.gov